Vanda Pharmaceuticals (VNDA) Assets (2010 - 2026)

Vanda Pharmaceuticals has disclosed Assets across 17 years of filings, most recently posting $433.5 million for Q1 2026.

• Assets for Q1 2026 came in at $433.5 million, down 31.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $433.5 million (down 31.4% YoY), and the FY2025 annual result was $488.9 million, down 25.49% from the prior year.
• Assets came in at $433.5 million for Q1 2026 at Vanda Pharmaceuticals, down from $488.9 million in the prior quarter.
• In the past five years, Assets ranged from a high of $656.2 million in Q4 2024 to a low of $433.5 million in Q1 2026.
• The 5-year median for Assets is $634.2 million (2022), against an average of $613.6 million.
• Across the five-year window, Assets increased 11.11% in 2022 and plunged 31.4% in 2026, its largest moves.
• Vanda Pharmaceuticals' Assets stood at $634.2 million in 2022, then advanced by 2.24% to $648.4 million in 2023, then grew by 1.2% to $656.2 million in 2024, then retreated by 25.49% to $488.9 million in 2025, then slipped by 11.34% to $433.5 million in 2026.
• The last three Assets figures came in at $433.5 million (Q1 2026), $488.9 million (Q4 2025), and $601.1 million (Q3 2025), per Business Quant data.